Perspective Therapeutics shares surge 53.69% intraday after $175M follow-on offering priced at $3.79.

Perspective Therapeutics surged 53.69% intraday after announcing a $175 million follow-on offering, including 46.2 million shares and pre-funded warrants priced at $3.79 per share. The offering, led by major investment banks, aims to fund clinical development, manufacturing expansion, and potential acquisitions. The pricing aligned with the stock’s prior close, signaling market confidence. The move follows a prior 66% surge on January 29, driven by Sanofi’s deprioritization of a competing therapy, but the immediate catalyst was the capital raise to advance its radiopharmaceutical pipeline. The offering’s scale and strategic use of proceeds reinforced investor optimism about the company’s growth prospects in oncology.